Viyash Scientific FY26 Revenue ₹34,203 Million, Up 13.8% YoY; EBITDA at ₹7,025 Million, Up 59.6%
Viyash Scientific reported FY26 revenue of ₹34,203 million, a 13.8% YoY increase, and EBITDA of ₹7,025 million, up 59.6% YoY. Q4 revenue was ₹9,200 million, up 19.1% YoY, with EBITDA at ₹2,001 million. Net debt to LTM EBITDA improved to 0.2x from 1.0x in FY25. The company's merger is approved, focusing on synergy realization, and evaluating inorganic growth opportunities.
The announcement indicates a strong financial performance, successful merger, and strategic initiatives, which will likely have a positive impact on the company's future prospects.
The announcement highlights strong financial performance with significant revenue and EBITDA growth, successful merger integration, and a positive outlook for future growth and strategic initiatives.
Viyash Scientific Limited (formerly known as Sequent Scientific Limited) announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Fiscal year 2026 was a transformative year for Viyash Scientific, marked by the successful integration of facilities, operations, and corporate functions into one unified platform. Q4 was the strongest quarter in the company’s history, with merger synergies beginning to reflect meaningfully in the financial performance. The integrated platform has strengthened execution, improved operating leverage, and enhanced resilience amidst ongoing geopolitical and maritime disruptions. The company continues to navigate these challenges through disciplined asset utilization, cost controls, and agile pricing strategies. As Viyash Scientific enters FY27, they are excited about the product pipeline and growth roadmap and are also actively evaluating selective inorganic opportunities to further strengthen the platform and create long-term value.
In Q4 FY26, revenues reached ₹9,200 million, up 19.1% year-over-year, with an EBITDA of ₹2,001 million, a 63.8% increase year-over-year, and an EBITDA margin of 21.7%. The net debt to LTM EBITDA stood at 0.2x, a significant reduction from 1.0x in FY25. For the full fiscal year 2026, revenues were ₹34,203 million, up 13.8% year-over-year, with an EBITDA of ₹7,025 million, a 59.6% increase year-over-year, and an EBITDA margin of 20.5%.
Key highlights from Q4 FY26 include the completion of 2 regulatory audits, 36 customer audits, facility inspections, regulatory approvals, and product launches. The company filed 4 APIs and 1 FDF, completed validations for 4 APIs and 3 FDFs, and has 6 APIs and 1 FDF in the R&D pipeline. The merger has been approved by all regulatory authorities and is in effect, with a focus on synergy realization for the next 12 months. R&D teams have been co-located, leading to accelerated development, and manufacturing is utilizing available low-cost capacity through the group.
What to do with a filing like this
Viyash Scientific Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Viyash Scientific Limited. Read the original for the full detail.